Medicaid policies to contain psychiatric drug costs

被引:45
|
作者
Koyanagi, C [1 ]
Forquer, S
Alfano, E
机构
[1] Bazelon Ctr Mental Hlth Law, Washington, DC USA
[2] Univ Colorado Hlth & Sci, Dept Psychiat, Boulder, CO 80309 USA
[3] Comprehens Neurosci Inc, Colorado Springs, CO USA
关键词
D O I
10.1377/hlthaff.24.2.536
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
This study reviews Medicaid policies to restrict access to psychiatric medications. Policies on prior authorization, preferred drug lists, limitations on the number of prescriptions, fail-first requirements, and use of generics are reviewed. All states apply one or more of those policies to medications for mental illness, and many apply several. A large number of states have legislated exemptions from those policies for certain medications, particularly antipsychotics and antidepressants. Other psychiatric medications are less well protected. Some states appear to restrict access severely. Questions have been raised as to whether these policies actually save money in the long term.
引用
收藏
页码:536 / 544
页数:9
相关论文
共 50 条
  • [2] Medicaid preferred drug lists' costs to physicians
    Ketcham, Jonathan D.
    Epstein, Andrew J.
    MEDICAL CARE, 2008, 46 (01) : 9 - 16
  • [3] POTENTIAL IMPACT OF PREPAYMENT ON MEDICAID DRUG COSTS
    YESALIS, CE
    NORWOOD, GJ
    LIPSON, DP
    CONTEMPORARY PHARMACY PRACTICE, 1979, 2 (02) : 87 - 94
  • [4] Medicaid preferred drug lists' costs to physicians
    Ketcham, J. D.
    Epstein, A. J.
    VALUE IN HEALTH, 2007, 10 (03) : A4 - A5
  • [5] State initiatives to control medicaid drug costs
    Weiner, M
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (18): : 1912 - 1912
  • [6] Who bears the burden of Medicaid drug copayment policies?
    Stuart, B
    Zacker, C
    HEALTH AFFAIRS, 1999, 18 (02) : 201 - 212
  • [7] A COMPARISON OF HOSPITAL RESPONSES TO REIMBURSEMENT POLICIES FOR MEDICAID PSYCHIATRIC-PATIENTS
    FRANK, RG
    LAVE, JR
    RAND JOURNAL OF ECONOMICS, 1989, 20 (04): : 588 - 600
  • [8] Sources of variation in drug costs among state Medicaid programs
    Brown, J
    Menzin, J
    Friedman, M
    VALUE IN HEALTH, 2003, 6 (03) : 204 - 204
  • [9] Reviews of Utah Medicaid high utilizers to control drug costs
    Oderda, GM
    Gunning, K
    LaFleur, J
    Stockdale, W
    Tyler, L
    Parke, D
    Orlando, P
    Brixner, D
    VALUE IN HEALTH, 2003, 6 (03) : 206 - 206
  • [10] THE COSTS OF INTERRUPTING ANTIHYPERTENSIVE DRUG-THERAPY IN A MEDICAID POPULATION
    MCCOMBS, JS
    NICHOL, MB
    NEWMAN, CM
    SCLAR, DA
    MEDICAL CARE, 1994, 32 (03) : 214 - 226